Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. (NKTX)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference. At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, “Cell Therapy in Autoimmune: State of the Art and What Comes Next.” Later that afternoon, Nkarta President Nadir Mahmood will participate in a 3:45 p.m ET fireside chat to share updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases. A simultaneous webcast of the fireside chat will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days.About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic,
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta rises on FDA agreement for amended trial protocol [Seeking Alpha]Seeking Alpha
- Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers [Yahoo! Finance]Yahoo! Finance
- Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersGlobeNewswire
- Nkarta (NKTX) had its price target lowered by Mizuho from $14.00 to $12.00. They now have an "outperform" rating on the stock.MarketBeat
- Nkarta (NKTX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NKTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sell"MarketBeat
NKTX
Earnings
- 3/25/26 - Miss
NKTX
Sec Filings
- 4/6/26 - Form EFFECT
- 4/3/26 - Form 424B5
- 3/26/26 - Form 8-K
- NKTX's page on the SEC website